[Survival analysis of adjustable continence therapy device (ACT®/proACT®): a new message for patients].

摘要: Introduction The main purpose was to assess the failure free survival of adjustable continence therapy ACT®/proACT® after obtained and seek factors influencing it. Material methods Retrospective, single-center study peri-urethral balloons implanted between 2007 2014. Efficacy defined by wearing 0 or 1 safety pad per day. primary end point time estimated from a curve (Kaplan-Meier). Factors that could influence were: sex, age, radiotherapy, diabetes, number before surgery, balloon inflation, early complications, mixed urinary incontinence previous placement. They were analyzed in COX regression. Results Of 82 placed, 41 effective 36 patients. 50 % at 60 months. Radiotherapy, diabetes placement appeared significantly decrease (P=0.031;P=0.025;P=0.029, respectively). Fifteen still last follow-up, one lost follow-up 25 required re-intervention for loss efficacy. cause efficacy system leakage. Fifty-two percent became ineffective replaced new 28% an artificial sphincter. Conclusion Patients who continent with (ACT®/proACT®) had surgery probability 5 years Radiotherapy seems be risk factor loss. Level evidence IV.